Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Agarwala SS, Ferri W, Gooding W and Kirkwood JM (1999) A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 85(9): 1979–1984
Ahman D, Creagan E, Hahn R, Edmonson J, Bisel H and Schaid D (1989) Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 3: 224–227
Balch C (1992) Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 8: 400–414
Cocconi G, Bella M and Calabresi F (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New Engl J Med 327: 516–523
Creagan E, Schaid DDLA and Frytak S (1990) Disseminated malignant melanoma and recombinant interferon: Analysis of seven consecutive phase II investigations. J Invest Dermatol 95: 188S–192S
Creagan ET, Dalton RJ and Ahmann DL (1995) Randomized surgical adjuvant clinical trial on recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13: 2776–2783
DelPrete SA, Maurer LH, O’Donnel J, Forcier FJ and Le Marbre P (1984) Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403–1405
Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U and Ingvar C (1998) Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer 34(9): 1368–1374
Keilholz U, Conradt C, Legha S, Khayat D, Scheibenbogen C and Thatcher N (1998) Results of IL-2-based treatment in advanced melanoma: a case-record based analysis of 631 patients. J Clin Oncol 16(9): 2921–2929
Keilholz U, Goey S, Punt C, Proebstle T, Salzmann R and Scheibenbogen C (1997) IFNa/IL-2 with or without Cisplatinum in metastatic melanoma: a randomized trial of the EORTC Melanoma Cooperative Group. J Clin Oncol 15: 2579–2588
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC and Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7–17
Kirkwood JM, Ibrahim J and Sondak V (1999) Preliminary analysis of the E1690/S9111/C9190 Intergroup Postoperative Adjuvant Trial of high- and low-dose IFNalpha2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma. Proc Am Soc Clin Oncol 18: 2072
McClay EF, Mastrangelo MJ, Bellet RE and Berd D (1987) Combination chemo/hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71: 465–469
McClay EF, Albright KA, Jones JA, Christen R and Howell SB (1993) Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53: 1571–1576
McClay EF, McClay MET, Monroe L, Baron PL, Cole DJ, O’Brien PH, Metcalf JS and Maize JC (2000) The effect of tamoxifen and cisplatin on the disease free and overall survival of patients with high-risk melanoma. Br J Cancer xx: 00–00
Rusthoven J, Quirt I and Iscoe N (1996) Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14: 2083–2090
Saxman S, Meyers M, Chapman P, Destro A, Panageas K and Begg C (1999) A phase III multicenter randomized trial of DTIC, cisplatin, BCNU ad tamoxifen versus DTIC alone in patients with metastatic melanoma [Abstract]. In: Proceedings of ASCO, 1999. Melanoma and Sarcoma, 536a
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keilholz, U., Suciu, S. & Eggermont, A. What can we learn from phase II adjuvant trials in melanoma?. Br J Cancer 83, 6–7 (2000). https://doi.org/10.1054/bjoc.2000.1277
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1277
This article is cited by
-
New target-based agents involve new clinical trial designs
Clinical and Translational Oncology (2006)